Cullinan Oncology’s shares reached a 52-week high of $23.07 on Tuesday, extending a 200% gain over the past 12 months and a 122% year-to-date advance.
The biotechnology company’s market capitalization now stands at approximately $1.48 billion. UBS upgraded its price target on Cullinan Oncology to $27 from a prior valuation, while maintaining a Buy rating. William Blair also reiterated an Outperform rating for the stock.
Clinical progress supported the rally. Positive results from the Phase 3 REZILIENT3 trial showed that zipalertinib combined with chemotherapy significantly improved progression-free survival in patients with non-small cell lung cancer. Separately, Cullinan Therapeutics received early regulatory feedback from the FDA on CLN-049, a drug targeting acute myeloid leukemia, with plans to initiate a Phase 2 study by the third quarter of 2026.
The company also highlighted developments in its autoimmune pipeline. Clinical data for CLN-978 and velinotamig were presented at an immunology-focused event in New York City, with candidates targeting systemic lupus erythematosus and lupus nephritis. At its annual stockholder meeting, Cullinan elected two new Class III directors to serve three-year terms.
InvestingPro analysis suggested the stock may be overvalued relative to its fair value estimate, though it provided additional proprietary insights for subscribers.
